Egypt’s metabolic dysfunction associated steatotic liver disease: Genetic and dietary nexus, shaping artificial intelligence driven healthier future

Table 3 Various clinical and laboratory parameters between metabolically dysfunction-associated steatotic liver disease and healthy participants, stratified by age, median (range)

	MASLD (< 38 years)	Non-MASLD (< 38 years)	P value	MASLD (≥ 38 years)	Non-MASLD (≥ 38 years)	P value
Lipoprotein lipase	16 (0.5-185)	19 (2-204)	0.300	13 (0.5-154)	16 (0.5-214)	0.817
L-carnitine	12.4 (1-58)	14 (1.2-58)	0.113	12.2 (0.1-63)	12.8 (0.6-43)	0.899
C-reactive protein	3.6 (0.3-56)	2 (0.3-33)	< 0.001	4.3 (0.3-117)	2.8 (0.2-39.2)	< 0.001
Aspartate aminotransferase	19 (8-114)	18 (9-103)	< 0.001	20 (4.5-236)	19 (10-42)	0.045
Alanine aminotransferase	21 (4-156)	14 (4-82)	< 0.001	20 (5-258)	15 (3-53)	< 0.001
Gamma-glutamyl transferase	21 (7-242)	13.5 (4-99)	< 0.001	24 (4-595)	17.5 (6-137)	< 0.001
Bilirubin	0.4 (0.1-1.9)	0.4 (0.1-54)	0.098	0.4 (0.1-2)	0.4 (0-1.2)	0.149
Homeostasis Model Assessment of Insulin Resistance	2.2 (0.1-73)	1.4 (0-10.7)	< 0.001	2.2 (0.1-31.9)	1.4 (0.1-20.2)	< 0.001
Fasting insulin	9.9 (0.3-279.4)	7 (0.3-45)	< 0.001	9.9 (0.3-109.7)	6.7 (0.3-39.1)	< 0.001
Triglycerides	104 (36-354)	68.5 (28-392)	< 0.001	130 (3.9-1086)	96.5 (43-409)	< 0.001
Very low-density lipoproteins	20.8 (7-70.8)	13.7 (5.8-78.4)	< 0.001	26 (3.1-217.2)	19.6 (8.6-81.8)	< 0.001
Thyrotropin	1.7 (0.01-100)	1.5 (0.01-9.7)	0.007	1.5 (0.01-16)	1.5 (0.01-6.6)	0.650

MASLD: Metabolically dysfunction-associated steatotic liver disease.